Histologic grade is a better predictor of specific survival than Ki67 in localized ER+/HER2-breast cancer: a real-world study

被引：0
|
作者：
Sanchez, Cesar
Alejandro, Cataldo
Walbaum, Benjamin
Acevedo, Francisco
Constabel, Christine
Saure, Antoine
Rey, Pablo
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-18-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-18-02
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Metastatic HR+/HER2-Breast Cancer Real-World Data support the clinical Benefits of Palbociclib
    Schoellmann, Claudia
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [42] Ki67 Proliferative Index as an Invaluable Biomarker in Hormone Receptor (HR)-Positive Breast Cancer: Ki67 Labelling Index Can Reflect the Differences between Luminal A and B Subtypes Better Than HER2 Expression
    Park, Y. H.
    Ok, O-N
    Seo, J. J.
    Cho, E. Y.
    Lee, J. E.
    Nam, S. J.
    Yang, J. H.
    Ahn, J. S.
    Im, Y-H.
    CANCER RESEARCH, 2010, 70
  • [43] Effect of adjuvant chemotherapy in patients with ER+/HER2-breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status
    Tanaka, Natsuko
    Hirano, Akira
    Hattori, Akinori
    Ogura, Kaoru
    Kamimura, Mari
    Inoue, Hiroaki
    Yukawa, Hiroko
    Sakaguchi, Shiho
    Matsuoka, Aya
    Kodera, Asaka
    Shimizu, Tadao
    BREAST CANCER, 2021, 28 (01) : 40 - 47
  • [44] Degree of PgR expression is a more potent prognostic factor than Ki67 labeling index in ER-positive and HER2-negative breast cancer
    Kurozumi, S.
    Matsumoto, H.
    Hayashi, Y.
    Kurosumi, M.
    Toduka, K.
    Kubo, K.
    Nagai, E. S.
    Inoue, K.
    Horiguchi, J.
    Takeyoshi, I.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S193 - S193
  • [45] A multinational study of real-world treatment patterns among patients with early stage HR+/HER2-breast cancer (BC)
    Criscitiello, C.
    Spurden, D.
    Rider, A.
    Williams, R.
    Corsaro, M.
    Pike, J.
    Law, E. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S42 - S43
  • [46] Treatment patterns and clinical outcomes in ER+/HER2-metastatic breast cancer in German real world settings
    Mitra, D.
    Kurosky, S.
    Kaye, J.
    Harbeck, N.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S141 - S141
  • [47] Phase Ib/Il study of ribociclib and alpelisib and letrozole in ER+, HER2-breast cancer: Safety, preliminary efficacy and molecular analysis
    Juric, D.
    Ismail-Khan, R.
    Campone, M.
    Garcia-Estevez, L.
    Becerra, C.
    De Boer, R.
    Hamilton, E.
    Mayer, I. A.
    Hui, R.
    Lathrop, K. I.
    Pagani, O.
    Asano, S.
    Bhansali, S. G.
    Zhang, V.
    Hewes, B.
    Munster, P.
    CANCER RESEARCH, 2016, 76
  • [48] REAL-WORLD DATA: IMPACT OF LOW HER-2 EXPRESSION IN METASTATIC HR+/HER2-BREAST CANCER TREATED WITH PALBOCICLIB
    Montenegro, Maria Alexandra
    Simao, Diana Cardoso
    Mendes, Jose Leao
    Fernandes, Leonor Raposo
    Martins, Maria Manuela
    Da Luz, Ricardo
    Oliveira, Sonia Duarte
    BREAST, 2023, 71 : S57 - S58
  • [49] Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, Her2-breast cancer.
    Munster, Pamela N.
    Hamilton, Erika Paige
    Estevez, Laura G.
    De Boer, Richard H.
    Mayer, Ingrid A.
    Campone, Mario
    Asano, Shizuka
    Bhansali, Suraj
    Zhang, Vickie
    Hewes, Becker
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [50] Real-world survival of Danish patients with HER2-positive metastatic breast cancer
    Artzi, Daniel
    Berg, Tobias
    Celik, Alan
    Kumler, Iben
    Kenholm, Julia
    Al-Rawi, Sami
    Jensen, Maj-Britt
    Andersson, Michael
    Knoop, Ann
    ACTA ONCOLOGICA, 2023, 62 (06) : 601 - 607
12345